Skip to content

Evaluation of the F&P Toffee Nasal Pillows Mask, US, 2022

Evaluation of the F&P Toffee Nasal Pillows Mask, US, 2022

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05573763
Enrollment
40
Registered
2022-10-10
Start date
2022-11-14
Completion date
2023-06-16
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Brief summary

The purpose of this clinical investigation is to evaluate the performance and safety of the F&P Toffee nasal pillows mask in a home environment.

Interventions

DEVICEF&P Toffee

Nasal pillows mask

Sponsors

Fisher and Paykel Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Persons who are ≥22 years of age * Persons who weigh ≥66 pounds * Persons who have been prescribed PAP therapy by a physician * Persons who are existing nasal pillows mask users with at ≥3 months of use prior to enrolment in the clinical trial * Persons who are compliant with PAP therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical trial * Persons who are fluent in spoken and written English * Persons who possess the capacity to provide informed consent

Exclusion criteria

* Persons who are intolerant to PAP therapy * Persons who possess, or suffer from, anatomical or physiological conditions which make PAP therapy inappropriate * Persons who are required to use PAP therapy for \>12 hours per day or for extensive periods, not including sleep or naps * Persons who are trying to get pregnant, are pregnant, or think they may be pregnant * Persons who have an IPAP pressure of \>25 cmH2O if on BPAP * Persons who use a PAP therapy device for the delivery of medicines, except supplemental O2 * Persons who use a PAP therapy device that does not possess data recording capabilities to capture AHI and a numerical indicator of leak that is accessible to the investigation site

Design outcomes

Primary

MeasureTime frameDescription
Therapeutic EfficacyBaseline and 14±5 daysDetermined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe
Epworth Sleepiness Scale14±5 daysAll relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

Countries

United States

Participant flow

Participants by arm

ArmCount
F&P Toffee: Nasal Pillows Mask
Participants to use nasal pillows mask for 14 days. Toffee Nasal Pillows Mask: Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
39
Total39

Baseline characteristics

CharacteristicF&P Toffee: Nasal Pillows Mask
Age, Customized
22+ years of age
39 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
36 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
23 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 39
other
Total, other adverse events
2 / 39
serious
Total, serious adverse events
0 / 39

Outcome results

Primary

Epworth Sleepiness Scale

All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

Time frame: 14±5 days

ArmMeasureValue (MEAN)
F&P Toffee: Nasal Pillows MaskEpworth Sleepiness Scale10 Scores on a scale
Primary

Therapeutic Efficacy

Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe

Time frame: Baseline and 14±5 days

ArmMeasureValue (MEAN)
F&P Toffee: Nasal Pillows MaskTherapeutic Efficacy2 events per hour

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026